

AlphaLISA® SureFire® Ultra™

Human p-IRF5 (Ser446) Detection Kit

Product number: ALSU-PIRF5-A-500, ALSU-PIRF5-A10K,
ALSU-PIRF5-A50K, ALSU-PIRF5-A-HV



Kit specificity:


This assay kit contains antibodies which recognize the phospho Ser-446 epitope and a distal epitope on Interferon regulatory factor 5 (IRF5). The protein detected by this kit corresponds to UniProt ID Q13568. These antibodies recognize IRF5 of human origin. Other species should be tested on a case-by-case basis.

Control lysate information:


Positive Control Lysate: Prepared from THP-1 cells, seeded at 0.3×10^6 cells/mL and incubated for 48 hours in T175 flasks in 10% FBS containing medium. Cells were harvested, resuspended at 5×10^6 cells/mL and then treated with 100 nM Calyculin A for 3 hours. Cells were washed in HBSS + 0.1% BSA and lysed in Lysis Buffer at a final cell density of 8×10^6 cells/mL.

Representative data:


Data obtained with a 2-plate, 2-incubation protocol. RPMI 8226 cells were seeded at 500K cells/well in a 96 well plate. Cells were treated with CpG ODN-2006 at the indicated concentrations for 6 hours. After treatment, cells washed in HBSS + 0.1% BSA and lysed with Lysis Buffer. Cell lysates were assayed separately for Phospho (Ser446) and Total IRF5 using respective *SureFire Ultra* kits. Equivalent to approximately 50,000 cells/datapoint.







Data obtained with a 2-plate, 2-incubation protocol. RPMI 8226 cells were seeded at 200K cells/well in a 96 well plate. Cells were treated with CpG ODN-1668 at the indicated concentrations for 6 hours. After treatment, cells were washed in HBSS + 0.1% BSA and lysed with Lysis Buffer. Cell lysates were assayed separately for Phospho (Ser446) and Total IRF5 using respective *SureFire Ultra* kits. Equivalent to approximately 20,000 cells/datapoint.




Data obtained with a 2-plate, 2-incubation protocol. RPMI 8226 cells were seeded at 200K cells/well in a 96 well plate. Cells were treated with 1 µM Resiquimod (R848) at the indicated timepoints. After time course, cells were washed in HBSS + 0.1% BSA and lysed with Lysis Buffer. Cell lysates were assayed for IRF5 Phospho (Ser446) using *SureFire Ultra*. Equivalent to approximately 20,000 cells/datapoint.



Data obtained with a 2-plate, 2-incubation protocol. RPMI 8226 cells were seeded at various densities in a 96 well plate. Cells were treated with CpG ODN-2006 at the indicated concentrations for 6 hours. After treatment, cells were washed in HBSS + 0.1% BSA and lysed with Lysis Buffer. Cell lysates were assayed separately for Phospho (Ser446) and Total IRF5 using respective *SureFire Ultra* kits. Approximate number of cells/datapoint is outlined above each graph.



Data obtained with a 2-plate, 2-incubation protocol. THP-1 cells were seeded at 400K cells/well in a 96 well plate. Cells were then treated with Calyculin A at the indicated concentrations for 3 hours. Cells were washed in HBSS + 0.1% BSA and lysed with Lysis Buffer. Cell lysates were assayed separately for Phospho (Ser446) and Total IRF5 using respective *SureFire Ultra* kits. Equivalent to approximately 40,000 cells/datapoint.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF"

